Roughly half a year after the close of its deal to acquire Bayer spinout AiCurus, Asahi Kasei’s $920 million bet has paid off ...

Most manufacturers know Inmar for pharmacy returns and consumer drug takeback programs. | Emily Welker explains how retail ...

The pharmaceutical patient journey has always been complex, but today's media environment presents more touchpoints than ever ...

Life sciences organizations have invested heavily in data and analytics, yet timely decision making remains a challenge. | ...

Livmarli significantly improved severe itching caused by rare liver diseases. With the phase 3 win in hand, Mirum is looking for a third indication from the FDA early next year.

Less than four years after returning to Bausch + Lomb to lead the eye health company following its split from Bausch Health, ...

Invenra has created playing cards featuring artwork by people affected by cancer as it seeks biopharma buy-in for its ...

AI is transforming healthcare by making guidelines, clinical trial data and emerging research more accessible than ever. | AI delivers information. Peer validation delivers confidence. Learn how HCP ...

All told, GSK is plugging more than $800 million into an overhaul of its facilities in Upper Merion Township, where ...

Revolution Medicines’ stock slid 6.3% Thursday after newly released FDA review documents sparked investor unease around ...

With a Friday go-ahead from the FDA, another key piece of Teva’s innovation revamp strategy has fallen into place, further ...

After a year of rocky financials and trial readouts, Quince Therapeutics is charting a new path forward and relaunching with ...